Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Wei Li, Junji Tsurutani, Naoto T. Ueno, Khalil Zaman, Aleix Prat, Konstantinos Papazisis, Hope S. Rugo, Toshinari Yamashita, Nadia Harbeck, Seock-Ah Im, Michelino De Laurentiis, Jean-Yves Pierga, Xiaojia Wang, Andrea Gombos, Eriko Tokunaga, Cecilia Orbegoso Aguilar, Lotus Yung, Feng Xiao, Yingkai Cheng, David Cameron

Open source

DOI: 10.1038/s41591-025-03981-4
Published: 2025-10-08
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03981-4,
  title = {Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial},
  author = {Shanu Modi and William Jacot and Hiroji Iwata and Yeon Hee Park and Maria Vidal Losada and Wei Li and Junji Tsurutani and Naoto T. Ueno and Khalil Zaman and Aleix Prat and Konstantinos Papazisis and Hope S. Rugo and Toshinari Yamashita and Nadia Harbeck and Seock-Ah Im and Michelino De Laurentiis and Jean-Yves Pierga and Xiaojia Wang and Andrea Gombos and Eriko Tokunaga and Cecilia Orbegoso Aguilar and Lotus Yung and Feng Xiao and Yingkai Cheng and David Cameron},
  year = {2025},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-025-03981-4},
  url = {https://doi.org/10.1038/s41591-025-03981-4}
}

RIS

TY  - JOUR
TI  - Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
AU  - Shanu Modi
AU  - William Jacot
AU  - Hiroji Iwata
AU  - Yeon Hee Park
AU  - Maria Vidal Losada
AU  - Wei Li
AU  - Junji Tsurutani
AU  - Naoto T. Ueno
AU  - Khalil Zaman
AU  - Aleix Prat
AU  - Konstantinos Papazisis
AU  - Hope S. Rugo
AU  - Toshinari Yamashita
AU  - Nadia Harbeck
AU  - Seock-Ah Im
AU  - Michelino De Laurentiis
AU  - Jean-Yves Pierga
AU  - Xiaojia Wang
AU  - Andrea Gombos
AU  - Eriko Tokunaga
AU  - Cecilia Orbegoso Aguilar
AU  - Lotus Yung
AU  - Feng Xiao
AU  - Yingkai Cheng
AU  - David Cameron
PY  - 2025
JO  - Nature Medicine
DO  - 10.1038/s41591-025-03981-4
UR  - https://doi.org/10.1038/s41591-025-03981-4
ER  -

APA

Modi, S., Jacot, W., Iwata, H., Park, Y. H., Losada, M. V., Li, W., Tsurutani, J., Ueno, N. T., Zaman, K., Prat, A., Papazisis, K., Rugo, H. S., Yamashita, T., Harbeck, N., Im, S., Laurentiis, M. D., Pierga, J., Wang, X., Gombos, A., Tokunaga, E., Aguilar, C. O., Yung, L., Xiao, F., Cheng, Y., & Cameron, D. (2025). Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial. Nature Medicine. https://doi.org/10.1038/s41591-025-03981-4

Source records

crossref · retrieved 2026-09-26T03:29:24.396Z